prma digital applications

Drive payer submission readiness for your Phase 2 and 3 products

Encourage integrated decision-making between affiliate and global functions to build an evidence generation plan
Provide a systematic assessment of payer evidence readiness for your product against actual submission template requirements with a visual heatmap
Generate an organizational vision and action plan to anticipate and mitigate value challenges to optimize payer readiness

Understanding and adapting to evolving payer requirements is becoming increasingly important to managing market access risk and delivering commercial success. Rapid developments in the treatment landscape present new challenges for payers who have different perspectives on value and approaches to market access, while manufacturers are under pressure to bring products to market quickly.

  • Provides a robust situational analysis based on a consistent and systemized framework that rates your current evidence generation activities against the individual requirements from payer submission templates relevant to your asset

  • Presents a comprehensive summary of the evidence gaps with a red-amber-green rating of potential challenges, encouraging early clear and consistent communication across the organization

  • Accelerates HTA submission readiness by producing a high-quality evidence generation plan driven by informed, collaborative, and integrated decision-making

  • Identifies clear responsibilities across global, regional and affiliates for implementation, recognizing that not all gaps can or will be bridged

CASE STUDY

Over 40 readiness assessments successfully delivered by the PRMA Healthcheck® late module

PRMA Consulting is celebrating the successful support of over 40 readiness assessments using its digital application, the PRMA Healthcheck® late module. Created to drive payer submission readiness for Phase 2 and 3 products, the application is the result of 5 years’ collaboration with leading pharmaceutical companies to meet their market access challenges.

WHITEPAPER

How are digital applications transforming the value and access functions?

Pharmaceutical and biotechnology companies are turning to technology more frequently to solve business issues, and are increasingly using digital technology to optimize market access for their products. We believe that there are three key benefits for market access.

A consumate piece of analysis with astute outputs, I look forward to making good use of it.
Senior Market Access Manager, top-5 pharmaceutical company

The work culminated in a very successful early launch meeting with live market feedback and sharing of early global strategy.
Director, Global HEOR, top-20 pharmaceutical company

Request a demonstration

Our user friendly applications and expert team have supported organizations around the world in achieving their goals. We are always happy to have an informal, confidential chat and help you re-think your market access challenges.

First name *

* Please enter your first name

Last name *

* Please enter your last name

Email *

* Please enter an email address
 

info@prmaconsulting.com
UK (HQ) +44 (0)1252 786284
US +1 (415) 655 6798

Company registration number: 05893400

Follow us


Members of